Death receptors as targets in cancer
- 26 July 2013
- journal article
- review article
- Published by Wiley in British Journal of Pharmacology
- Vol. 169 (8), 1723-1744
- https://doi.org/10.1111/bph.12238
Abstract
Anti-tumour therapies based on the use pro-apoptotic receptor agonists, including TNF-related apoptosis-inducing ligand (TRAIL) or monoclonal antibodies targeting TRAIL-R1 or TRAIL-R2, have been disappointing so far, despite clear evidence of clinical activity and lack of adverse events for the vast majority of these compounds, whether combined or not with conventional or targeted anti-cancer therapies. This brief review aims at discussing the possible reasons for the lack of apparent success of these therapeutic approaches and at providing hints in order to rationally design optimal protocols based on our current understanding of TRAIL signalling regulation or resistance for future clinical trials.This publication has 179 references indexed in Scilit:
- Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling NetworksCell, 2012
- Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumoursBritish Journal of Cancer, 2011
- Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC levelCell Death & Differentiation, 2010
- TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5Journal of Molecular Medicine, 2010
- Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancerBritish Journal of Cancer, 2010
- Radiation and anticancer drugs can facilitate mitochondrial bypass by CD95/Fas via c-FLIP downregulationCell Death & Differentiation, 2009
- Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancerJournal of Molecular Medicine, 2009
- Enhancement of Glioma Radiotherapy and Chemotherapy Response With Targeted Antibody Therapy Against Death Receptor 5International Journal of Radiation Oncology*Biology*Physics, 2008
- Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAILNature Medicine, 2007
- Mutations in the p53 gene occur in diverse human tumour typesNature, 1989